| Ytd | -89.86% | |
| 1y | -81.99% |
| Open | 0.28 | Prev Close | 0.29 | Low | 0.28 | High | 0.29 | Mkt Cap | 42.74M |
| Vol | 96.09K | Avg Vol | 298.29K | EPS | -0.38 | P/E | N/A | Forward P/E | -7.33 |
| Beta | 2.21 | Short Ratio | 42.18 | Inst. Own | 6.26% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-03 | 50-d Avg | 0.38 | 200-d Avg | 1.22 | 1yr Est | 9.50 |
IMMP News
With effect from the commencement of trading on the Nasdaq Global Market on 28 September 2026 (US Ea
Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report) was the recipient of a significant decrease in sho
Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report) crossed above its 50-day moving average during tra
SYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immu
Key Results from INSIGHT-003 – Data Cutoff – 27 March 2026Approximately 92% of patients enrolled in
SYDNEY, AUSTRALIA, July 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immu
LOS ANGELES, July 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action laws
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, reminds investors o
LOS ANGELES--(BUSINESS WIRE)---- $IMMP--IMMP Investors Have Opportunity to Lead Immutep Limited Secu
New York, New York--(Newsfile Corp. - July 2, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nation
LOS ANGELES, July 02, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights l
NEW YORK, July 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been
NEW YORK, July 01, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has
New York, New York--(Newsfile Corp. - June 30, 2026) - Bronstein, Gewirtz and Grossman, LLC, a natio
LOS ANGELES, June 30, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Immutep Limited, (“Immut
San Diego, California--(Newsfile Corp. - June 29, 2026) - Robbins LLP is Investigating Allegations t
LOS ANGELES, June 29, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights l
LOS ANGELES, June 29, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action law
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law
LOS ANGELES, June 29, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litiga
New York, New York--(Newsfile Corp. - June 26, 2026) - Bronstein, Gewirtz and Grossman, LLC, a natio
First-in-human Phase I study met its primary endpoint, demonstrating favourable safety and tolerabil
Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), advises that
US stocks rise, Nasdaq up 200 points; Tech shares lead gains. Morgan Stanley beats estimates. Allbir
Immutep stock jumps after FDA orphan drug tag for eftilagimod alfa, even as halted Phase 3 trial and
US stocks up on Wed, Dow +0.22%, NASDAQ +0.37%, S&P 500 +0.28%. Bank of America beats Q1 earning
NN Inc. (NNBR) rose in pre-market trading after announcing expected sales growth and raising full-ye
Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well to
Immutep announced the discontinuation of the TACTI-004 Phase 3 trial. The CEO expresses disappointme
Wall Street analysts changed outlook on top names. See ratings page for upgrades, downgrades, and in
US stocks mostly lower, Nasdaq drops 0.71%, Dow up 0.03%. Utilities up 1.2%, communication services
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday. U
Wall Street analysts change outlook on top companies. See analyst rating changes and their thoughts
Baird analyst Joel Beatty downgrades Immutep (NASDAQ:IMMP) from Outperform to Neutral and lowers
The Oncology Institute (TOI) stock rose in pre-market trading after reporting better-than-expected f
Citizens analyst Reni J. Benjamin initiates coverage on Immutep (NASDAQ:IMMP) with a Market Outpe
Citizens analyst Reni J. Benjamin initiates coverage on Immutep (NASDAQ:IMMP) with a Market Outpe
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage
Immutep shares update on Phase I study of LAG-3 agonist antibody for autoimmune diseases, showing po
Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levels Dose depe
The registrational TACTI-004 Phase III has enrolled 289 patients globally, over 38% of the trial'
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage
Immutep Limited ((ASX: IMM, NASDAQ:IMMP) ("Immutep" or "the Company"), a late-stage